Use of magnetic resonance imaging to monitor iron overload

Hematology/Oncology Clinics of North America

Volumn 28, Issue 4, 2014, Pages 747-764

  Wood, John C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Chelation; Heart; Iron; Iron overload; Liver; Magnetic resonance imaging; Sickle cell disease; Thalassemia

Indexed keywords

FERRITIN; IRON; TRANSFERRIN; BIOLOGICAL MARKER;

BIOLOGICAL MONITORING; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DRUG LIVER LEVEL; FERRITIN BLOOD LEVEL; HEART; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; HYPOPHYSIS; IRON BLOOD LEVEL; IRON OVERLOAD; IRON STORAGE; KIDNEY; LIVER BIOPSY; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS; PRIORITY JOURNAL; REVIEW; SPLEEN; TRANSFERRIN BLOOD LEVEL; BLOOD; CARDIAC MUSCLE; LIVER; METABOLISM; PATHOLOGY;

BIOMARKERS; HUMANS; IRON; IRON OVERLOAD; KIDNEY; LIVER; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PANCREAS; SPLEEN;

EID: 84904758882     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.04.002     Document Type: Review

References (70)

1. Cohen A.R., Glimm E., Porter J.B. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood 2008, 111:583-587.
2. Angelucci E., Brittenham G.M., McLaren C.E., et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000, 343:327-331.
3. Brittenham G.M., Cohen A.R., McLaren C.E., et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993, 42:81-85.
4. Belhoul K.M., Bakir M.L., Saned M.S., et al. Serum ferritin levels and endocrinopathy in medically treated patients with beta thalassemia major. Ann Hematol 2012, 91:1107-1114.
5. Herbert V., Jayatilleke E., Shaw S., et al. Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. Stem Cells 1997, 15:291-296.
6. Kountouras D., Tsagarakis N.J., Fatourou E., et al. Liver disease in adult transfusion-dependent beta-thalassaemic patients: investigating the role of iron overload and chronic HCV infection. Liver Int 2013, 33:420-427.
7. Chapman R.W., Hussain M.A., Gorman A., et al. Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload. J Clin Pathol 1982, 35:487-491.
8. Musallam K.M., Cappellini M.D., Wood J.C., et al. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev 2012, 26(Suppl 1):S16-S19.
9. Puliyel M., Sposto R., Berdoukas V.A., et al. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload. Am J Hematol 2014, 89(4):391-394.
10. Crownover B.K., Covey C.J. Hereditary hemochromatosis. Am Fam Physician 2013, 87:183-190.
11. Wangruangsathit S., Hathirat P., Chuansumrit A., et al. The correlation of transferrin saturation and ferritin in non-splenectomized thalassemic children. J Med Assoc Thai 1999, 82(Suppl 1):S74-S76.
12. Pootrakul P., Breuer W., Sametband M., et al. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood 2004, 104:1504-1510.
13. Piga A., Longo F., Duca L., et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol 2009, 84:29-33.
14. Brittenham G.M., Griffith P.M., Nienhuis A.W., et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994, 331:567-573.
15. Angelucci E., Muretto P., Nicolucci A., et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002, 100:17-21.
16. Jensen P.D., Jensen F.T., Christensen T., et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003, 101:4632-4639.
17. Wood J.C., Kang B.P., Thompson A., et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010, 116:537-543.
18. Telfer P.T., Prestcott E., Holden S., et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000, 110:971-977.
19. Kanwar P., Kowdley K.V. Diagnosis and treatment of hereditary hemochromatosis: an update. Expert Rev Gastroenterol Hepatol 2013, 7:517-530.
20. Mancuso A. Hepatocellular carcinoma in thalassemia: a critical review. World J Hepatol 2010, 2:171-174.
21. Mancuso A. Management of hepatocellular carcinoma: enlightening the gray zones. World J Hepatol 2013, 5:302-310.
22. Noetzli L.J., Carson S.M., Nord A.S., et al. Longitudinal analysis of heart and liver iron in thalassemia major. Blood 2008, 112:2973-2978.
23. Wood J.C., Glynos T., Thompson A., et al. Relationship between LPI, LIC, and cardiac response in a deferasirox monotherapy trial. Haematologica 2011, 96(7):1055-1058.
24. Angelucci E., Baronciani D., Lucarelli G., et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol 1995, 89:757-761.
25. Ambu R., Crisponi G., Sciot R., et al. Uneven hepatic iron and phosphorus distribution in beta-thalassemia. J Hepatol 1995, 23:544-549.
26. Emond M.J., Bronner M.P., Carlson T.H., et al. Quantitative study of the variability of hepatic iron concentrations. Clin Chem 1999, 45:340-346.
27. Villeneuve J.P., Bilodeau M., Lepage R., et al. Variability in hepatic iron concentration measurement from needle-biopsy specimens. J Hepatol 1996, 25:172-177.
28. Koh T.S., Benson T.H., Judson G.J. Trace element analysis of bovine liver: interlaboratory survey in Australia and New Zealand. J Assoc Off Anal Chem 1980, 63:809-813.
29. Butensky E., Fischer R., Hudes M., et al. Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am J Clin Pathol 2005, 123:146-152.
30. Goldberg H.I., Cann C.E., Moss A.A., et al. Noninvasive quantitation of liver iron in dogs with hemochromatosis using dual-energy CT scanning. Invest Radiol 1982, 17:375-380.
31. Wood J.C., Mo A., Gera A., et al. Quantitative computed tomography assessment of transfusional iron overload. Br J Haematol 2011, 153:780-785.
32. Nielsen P., Engelhardt R., Fischer R., et al. Noninvasive liver-iron quantification by computed tomography in iron-overloaded rats. Invest Radiol 1992, 27:312-317.
33. Brittenham G.M., Farrell D.E., Harris J.W., et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982, 307:1671-1675.
34. Fischer R., Longo F., Nielsen P., et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003, 121:938-948.
35. Gianesin B., Zefiro D., Musso M., et al. Measurement of liver iron overload: noninvasive calibration of MRI-R2* by magnetic iron detector susceptometer. Magn Reson Med 2012, 67:1782-1786.
36. Ghugre N.R., Wood J.C. Relaxivity-iron calibration in hepatic iron overload: probing underlying biophysical mechanisms using a Monte Carlo model. Magn Reson Med 2011, 65:837-847.
37. St Pierre T.G., Clark P.R., Chua-Anusorn W., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005, 105:855-861.
38. Wood J.C., Enriquez C., Ghugre N., et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005, 106:1460-1465.
39. Hankins J.S., McCarville M.B., Loeffler R.B., et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 2009, 113:4853-4855.
40. Meloni A., Rienhoff H.Y., Jones A., et al. The use of appropriate calibration curves corrects for systematic differences in liver R2* values measured using different software packages. Br J Haematol 2013, 161:888-891.
41. Wood J.C., Zhang P., Rienhoff H., et al. Liver MRI is better than biopsy for assessing total body iron balance: validation by simulation. Blood 2013, 122:958.
42. Wood J.C., Zhang P., Rienhoff H., et al. R2 and R2* are equally effective in evaluating Chronic response to iron chelation. Am J Hematol 2014, 89(5):505-508.
43. 2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med 2006, 84:349-364.
44. Anderson L.J., Westwood M.A., Prescott E., et al. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol 2006, 115:106-108.
45. Gabutti V., Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996, 95:26-36.
46. Anderson L.J., Holden S., Davis B., et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001, 22:2171-2179.
47. Wood J.C., Otto-Duessel M., Aguilar M., et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation 2005, 112:535-543.
48. Ghugre N.R., Enriquez C.M., Gonzalez I., et al. MRI detects myocardial iron in the human heart. Magn Reson Med 2006, 56:681-686.
49. Carpenter J.P., He T., Kirk P., et al. On T2* magnetic resonance and cardiac iron. Circulation 2011, 123(14):1519-1528.
50. Kirk P., Roughton M., Porter J.B., et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009, 120:1961-1968.
51. Pennell D.J., Udelson J.E., Arai A.E., et al. Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart Association. Circulation 2013, 128(3):281-308.
52. Wood J.C. History and current impact of cardiac magnetic resonance imaging on the management of iron overload. Circulation 2009, 120:1937-1939.
53. Noetzli L.J., Coates T.D., Wood J.C. Pancreatic iron loading in chronically transfused sickle cell disease is lower than in thalassaemia major. Br J Haematol 2011, 152:229-233.
54. Noetzli L.J., Papudesi J., Coates T.D., et al. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 2009, 114:4021-4026.
55. Noetzli L.J., Mittelman S.D., Watanabe R.M., et al. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol 2012, 87:155-160.
56. Borgna-Pignatti C., Rugolotto S., De Stefano P., et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004, 89:1187-1193.
57. Vogiatzi M.G., Macklin E.A., Trachtenberg F.L., et al. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol 2009, 146:546-556.
58. Noetzli L.J., Panigrahy A., Mittelman S.D., et al. Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol 2012, 87:167-171.
59. Farmaki K., Tzoumari I., Pappa C., et al. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010, 148:466-475.
60. Noetzli L.J., Panigrahy A., Hyderi A., et al. Pituitary iron and volume imaging in healthy controls. AJNR Am J Neuroradiol 2012, 33:259-265.
61. Gburek J., Birn H., Verroust P.J., et al. Renal uptake of myoglobin is mediated by the endocytic receptors megalin and cubilin. Am J Physiol Renal Physiol 2003, 285:F451-F458.
62. Solecki R., von Zglinicki T., Muller H.M., et al. Iron overload of spleen, liver and kidney as a consequence of hemolytic anaemia. Exp Pathol 1983, 23:227-235.
63. Schein A., Enriquez C., Coates T.D., et al. Magnetic resonance detection of kidney iron deposition in sickle cell disease: a marker of chronic hemolysis. J Magn Reson Imaging 2008, 28:698-704.
64. Brewer C.J., Coates T.D., Wood J.C. Spleen R2 and R2* in iron-overloaded patients with sickle cell disease and thalassemia major. J Magn Reson Imaging 2009, 29:357-364.
65. Porter J.B. Concepts and goals in the management of transfusional iron overload. Am J Hematol 2007, 82:1136-1139.
66. Wood J.C., Origa R., Agus A., et al. Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica 2008, 93:917-920.
67. Wood J.C., Tyszka J.M., Ghugre N., et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle-cell disease. Blood 2004, 103:1934-1936.
68. Meloni A., Puliyel M., Pepe A., et al. Cardiac iron overload in sickle cell anemia. Blood 2013, 122:1013.
69. Wood J.C. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol 2007, 14:183-190.
70. Garbowski M., Carpenter J.P., Smith G., et al. Calibration of improved T2* method for the estimation of liver iron concentration in transfusional iron overload. Blood 2009, 114.